Illustration: Sarah Grillo/Axios
Lycia Therapeutics, a biotech targeting disease-causing extracellular proteins, raised $317.5 million pricing its upsized IPO at $18 per share.
Why it matters: Funds raised from the offering of 17.6 million shares will help the biotech advance two Phase 1 candidates.
